DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,865,213 B2 Sheth Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,865,213 B2 Sheth Et Al USOO8865213B2 (12) United States Patent (10) Patent No.: US 8,865,213 B2 Sheth et al. (45) Date of Patent: Oct. 21, 2014 (54) MODIFIED RELEASE PHARMACEUTICAL (52) U.S. Cl. COMPOSITIONS CPC ........... A6 IK3I/4422 (2013.01); A61 K9/5078 (2013.01); A61 K9/5042 (2013.01); A61 K (75) Inventors: Nitin Vadilal Sheth, Raleigh, NC (US); 9/5084 (2013.01); A61K 9/5026 (2013.01); Sunil Suresh Jog, Maharashtra (IN); 461s 9/2 ost (2013.01) Santosh Sadashiv Chothe, Maharashtra (58) folassification s 424/489: 514/264.1 e O SSCO Sea (IN); Sampada Hemant Tupe, USPC ................................ 424/489, 469: 514/264.1 Maharashtra (IN) See application file for complete search history. (73) Assignees: USV Limited (IN); Indicus Pharma (56) References Cited LLC, Raleigh, NC (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 4,892,741 A * 1/1990 Ohm et al. .................... 424/479 6,897.205 B2 * 5/2005 Beckert et al. ................ 514f159 U.S.C. 154(b) by 435 days. 2004/O126358 A1* 7/2004 Warne et al. ................. 424/85.2 2005/0020613 A1 1/2005 Boehmet al. ................. 514,282 (21) Appl. No.: 12/981,077 * cited by examiner (22) Filed: Dec. 29, 2010 Primary Examiner — Ali Soroush (65) Prior Publication Data (74) Attorney, Agent, or Firm — Schwegman Lundberg & Woessner, P.A. US 2011 FO159093 A1 Jun. 30, 2011 (57) ABSTRACT (30) Foreign Application Priority Data Disclosed herein are multiparticulate modified release phar maceutical compositions comprising: (a) a first portion com Dec. 30, 2009 (IN) ......................... 3018/MUMA2009 prising an active ingredient, at least one surfactant and at least one release modifying agent and (b) a second portion com (51) Int. Cl. prising an active ingredient and optionally a release modify A6 IK 9/26 (2006.01) ing agent. Particularly, the active ingredient in the first portion A6 IK 9/14 (2006.01) is a calcium channel blocker and the modified release com A 6LX 9/50 (2006.01) position is in the form of a multiparticulate tablet. A6 IK3I/4422 (2006.01) A6 IK9/20 (2006.01) 25 Claims, 2 Drawing Sheets U.S. Patent Oct. 21, 2014 Sheet 1 of 2 US 8,865,213 B2 Contparative dissolution of Nisoleipiae ER tablets 34ng in pH6.8 phosphate buffer with 1/e SLS 8 : 60 s as S Time (hrs.) rer Inovator's product(Sular 34mg) -- Example 1 Fig. 1 U.S. Patent Oct. 21, 2014 Sheet 2 of 2 US 8,865,213 B2 Comparative dissolution of Nisodipine ER tablets 34ang in pH6.8 phosphate buffer with 10 SES t s s s s : Time (hrs.) re. In oyator's product (Sulair 34 rig -- Example 2 Fig. 2 US 8,865,213 B2 1. 2 MODIFIED RELEASE PHARMACEUTICAL There exists a need for an improved multiparticulate for COMPOSITIONS mulation that would improve the bioavailability and release rate and would ameliorate the drawbacks of prior art compo RELATED APPLICATION sitions. This application claims the benefit of Indian Provisional OBJECT OF INVENTION Application No. 3018/MUM/2009, filed on Dec. 30, 2009, Entitled: MODIFIED RELEASE PHARMACEUTICAL One object of the invention is to provide a multiparticulate COMPOSITIONS, which application is incorporated in its modified release pharmaceutical composition comprising: entirety. 10 (a) a first portion and (b) a second portion, wherein the active ingredient in the first and second portion is same or belong to TECHNICAL FIELD OF THE INVENTION a different therapeutic class. Another object of the invention is to provide multiparticu The present invention relates to multiparticulate modified late modified release compositions in which a first portion of release compositions. More particularly, the invention relates 15 the active ingredient is released in a delayed manner upon to Solid oral dosage forms comprising multiparticulate modi administration and a second portion of the active ingredient is fied release compositions. released in an extended manner. BACKGROUND OF THE INVENTION Another object of the invention is to provide multiparticu late modified release composition comprising: (a) a first por Multiparticulate drug delivery systems are dosage form, tion providing the release of the active ingredient in a delayed which consists of multiple small discrete units, where each manner and (b) a second portion providing the release of the unit exhibits some intended characteristics. Multiparticulates active ingredient in an extended manner; wherein the active are well-known dosage forms that comprise a plurality of ingredient present in the first portion and that of the second particles for different therapeutic use of the drug. 25 portion is a Dihydropyridine calcium channel blocker, Such as Modified release formulation aims at minimizing the peak Nisoldipine. to-trough variation in drug plasma levels that are associated Yet another object of the invention is to provide multipar with conventional frequent dosage regimes. ticulate modified release compositions in which the active Several attempts have been made to develop formulations ingredient in the first portion is a calcium channel blocker and that provide a Zero-order release of the drug compound. Most 30 the active ingredient present in the second portion is selected of the modified release formulations today offer the release from the group comprising angiotensin-converting enzyme profile as a zero order, first order or have a delayed release inhibitor, beta-blocker, anti-angina agents, anti-arrhythmic profile. Combination of different types of release i.e. either agents, anti-ischaemic agents, vasodilators, bronchodilators, extended-release or delayed-release and combinations hypolipidaemic agents and antidiabetics. thereof can be achieved by multiparticulates in the dosage 35 Another object of the invention is to provide multiparticu form. However these also offer difficulty in achieving the late modified release compositions in which a first portion of right combination of pellets/particles or where a very high Nisoldipine is released in a delayed manner and a second dose needs to be given. portion of Nisoldipine is released in an extended manner. U.S. Pat. No. 4,892,741 discloses solid medicament prepa Another object of the invention is to provide multiparticu ration having a long-lasting action in the form of a press 40 late modified release compositions in which a first portion of coated tablet which containing dihydropyridine. The press Nisoldipine is provided in the form of delayed release pellets coated tablet comprises (a) a core which contains a dihydro and a second portion of Nisoldipine is provided in the form of pyridine in rapid-release form, and (b) a coat around the core, matrix granules. Particularly, said composition is in the form the coat containing a dihydropyridine in slow-release form. of a tablet. US20062 10631 discloses a multi-particulate, modified-re 45 Another object of the invention is to provide multiparticu lease pharmaceutical composition for the oral administration late modified release compositions in which the first portion of an active ingredient to the colon, said particles comprising of the active ingredient is release in a delayed or extended a core comprising an active ingredient or a pharmaceutically manner and the second portion of the active ingredient is acceptable salt or ester thereof, and optionally one or more released immediately upon administration. excipients; a first coating applied to the Surface of the core, 50 Another object of the invention is to provide multiparticu wherein said first coating is insoluble in gastric juice and in late modified release compositions in which both portions of intestinal juice below pH 7, but soluble in colonic intestinal active ingredients are released in an extended manner. juice; and a second coating applied to the Surface of the first coating. SUMMARY OF INVENTION Studies have shown that there are adverse effects with the 55 coat-core systems compared to other drug delivery systems. The present invention provides multiparticulate modified Further, the core-coat technology requires the use of special release pharmaceutical composition comprising: (a) a first ized equipment thereby rendering an expensive process of portion and (b) a second portion, wherein the active ingredi manufacture. ent in the first and second portion is same or belong to a Therefore, there still exists a need to formulate modified 60 different therapeutic class. release formulations containing two different portions of Particularly, said multiparticulate compositions releases active ingredient which will provide for modified release of one or more active ingredient(s) in a modified manner. the active ingredient and which will have reduced or no According to one aspect, the present invention provides a adverse effects compared to prior art compositions. There multiparticulate modified release pharmaceutical composi also exists a need to develop process which could be simple 65 tion comprising: and cost effective and would not involve any tedious tech (a) a first portion comprising an active ingredient, at least one niques. Surfactant and at least one release modifying agent; US 8,865,213 B2 3 4 (b) a second portion comprising an active ingredient and from about 40% to about 100% of Nisoldipine is released; optionally a release modifying agent. after about 12 hours, more than about 80% of Nisoldipine is Preferably, the active ingredient in the first portion is a released. calcium channel blocker. Preferably, the active ingredient in According to one aspect, the invention provides multipar the first portion and the second portion is a calcium channel 5 ticulate modified release pharmaceutical composition com blocker selected from the group comprising Nisoldipine, prising: Nifedipine, Nitrendipine, Nicardipine, Nimodipine, Felo (a) a first portion comprising Nisoldipine, at least one dipine, Amlodipine, Aranidipine, AZelnidipine, Barnidipine, Surfactant and at least one release modifying agent; Benidipine, Cilnidipine, Clevidipine, Efonidipine, Lacid (b) a second portion comprising Nisoldipine and optionally ipine, Lercanidipine, Manidipine, Nilvadipine, Nitrendipine 10 a release modifying agent. or Pranidipine.
Load more

Recommended publications
  • Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies
    Chinese Journal of Physiology 61(1): 1-13, 2018 1 DOI: 10.4077/CJP.2018.BAG516 Stimulatory Action of Telmisartan, an Antagonist of Angiotensin II Receptor, on Voltage-Gated Na+ Current: Experimental and Theoretical Studies Tzu-Tung Chang, Chia-Jung Yang, Yu-Chi Lee, and Sheng-Nan Wu Department of Physiology, National Cheng Kung University Medical College, Tainan 70101, Taiwan, Republic of China Abstract Telmisartan (Tel) is recognized as a non-peptide blocker of AT1R. Whether this agent has any direct effects on ion currents remains unexplored. In whole-cell current recordings, addition of Tel + increased the peak amplitude of voltage-gated Na (NaV) current (INa) accompanied by the increased time constant of INa inactivation in differentiated NSC-34 motor neuron-like cells. Tel-stimulated INa in these cells is unlinked to either blockade of AT1R or activation of peroxisome proliferator-activated receptor gamma (PPAR-γ). In order to explore how this compound affects the amplitude and kinetics of INa in neurons, a Hodgkin-Huxley-based (HH-based) model designed to mimic effect of Tel on the functional activities of neurons was computationally created in this study. In this framework, the parameter for h inactivation gating variable, which was changed in a stepwise fashion, was implemented + + to predict changes in membrane potentials (V) as a function of maximal Na (GNa), K conductance (GK), or both. As inactivation time course of INa was increased, the bifurcation point of V versus GNa became lower, and the range between subcritical and supercritical values at the bifurcation of V versus GK correspondingly became larger.
    [Show full text]
  • REVIEW Peroxisome Proliferator-Activated Receptors In
    199 REVIEW Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition P Froment, F Gizard1, D Defever2, B Staels1, J Dupont3 and P Monget3 INSERM U.418, UMR Communications Cellulaire et Différenciation, Hôpital Debrousse, 29 rue Soeur Bouvier, 69322 Lyon, France 1INSERM U.545, Institut Pasteur de Lille et Faculté de Pharmacie Université de Lille 2, 1 rue du Pr Calmette, 59019 Lille, France 2LMCB, Department of Molecular Biomedical Research, V.I.B., Technologiepark 927, B-9052 Ghent (Zwijnaarde), Belgium 3Physiologie de la reproduction et des comportements, UMR 6175 INRA-CNRS-Université F. Rabelais de Tours-Haras Nationaux, 37380 Nouzilly, France (Requests for offprints should be addressed to P Froment; [email protected]) Abstract Peroxisome proliferator-activated receptors (PPAR, granulosa cell proliferation and steroidogenesis in vitro. All PPAR/ and PPAR) are a family of nuclear receptors these recent data raise new questions about the biologic that are activated by binding of natural ligands, such as actions of PPARs in reproduction and their use in polyunsaturated fatty acids or by synthetic ligands. Syn- therapeutic treatments of fertility troubles such as PCOS thetic molecules of the glitazone family, which bind to or endometriosis. In this review, we first describe the roles PPAR, are currently used to treat type II diabetes and of PPARs in different compartments of the reproductive also to attenuate the secondary clinical symptoms fre- axis (from male and female gametogenesis to parturition), quently associated with insulin resistance, including poly- with a focus on PPAR. Secondly, we discuss the possible cystic ovary syndrome (PCOS). PPARs are expressed molecular mechanisms underlying the effect of glitazones in different compartments of the reproductive system on PCOS.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Open Full Page
    1288 Vol. 8, 1288–1294, May 2002 Clinical Cancer Research Nuclear Receptor Agonists As Potential Differentiation Therapy Agents for Human Osteosarcoma1 Rex C. Haydon,2 Lan Zhou,2 Tao Feng, Conclusions: Our findings suggest that PPAR␥ and/or Benjamin Breyer, Hongwei Cheng, Wei Jiang, RXR ligands may be used as efficacious adjuvant therapeu- tic agents for primary osteosarcoma, as well as potential Akira Ishikawa, Terrance Peabody, chemopreventive agents for preventing the recurrence and Anthony Montag, Michael A. Simon, and metastasis of osteosarcoma after the surgical removal of the Tong-Chuan He3 primary tumors. Molecular Oncology Laboratory, Department of Surgery, The University of Chicago Medical Center, Chicago, Illinois 60637 INTRODUCTION Osteosarcoma is the most common primary malignant tu- mor of bone, encompassing a class of osteoid-producing neo- ABSTRACT plasms that range in clinical behavior and responsiveness to Purpose: This study was designed to investigate therapeutic regimens (1, 2). Best known of these lesions, the whether nuclear receptor agonists can be used as potential classic high-grade osteosarcoma primarily afflicts individuals in differentiation therapy agents for human osteosarcoma. the second decade of life and is distinguished by its locally Experimental Design: Four osteosarcoma cell lines aggressive character and early metastatic potential. Metastatic (143B, MNNG/HOS, MG-63, and TE-85) were treated with disease is often not apparent at diagnosis and causes the over- proliferator-activated receptor (PPAR)␥ agonists, troglita- whelming majority of deaths among patients with this disease. zone and ciglitazone, and a retinoid X receptor (RXR) li- Recurrent or metastatic tumors are significantly less sensitive, if gand, 9-cis retinoic acid.
    [Show full text]
  • New Mechanism-Based Anticancer Drugs That Act As Orphan
    NEW MECHANISM-BASED ANTICANCER DRUGS THAT ACT AS ORPHAN NUCLEAR RECEPTOR AGONISTS A Dissertation by SUDHAKAR REDDY CHINTHARLAPALLI Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY May 2006 Major Subject: Biochemistry NEW MECHANISM-BASED ANTICANCER DRUGS THAT ACT AS ORPHAN NUCLEAR RECEPTOR AGONISTS A Dissertation by SUDHAKAR REDDY CHINTHARLAPALLI Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Approved by: Chair of Committee, Stephen Safe Committee Members, David Peterson James Sacchettini Robert Burghardt Head of Department, Gregory Reinhart May 2006 Major Subject: Biochemistry iii ABSTRACT New Mechanism-Based Anticancer Drugs That Act as Orphan Nuclear Receptor Agonists. (May 2006) Sudhakar Reddy Chintharlapalli, B.V.M., College of Veterinary Science, Acharya N.G.Ranga Agricultural University, India; M.S., Texas A&M University-Kingsville Chair of Advisory Committee: Dr. Stephen Safe 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes containing p- trifluoromethyl (DIM-C-pPhCF3), p-t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C- pPhC6H5) substituents have been identified as a new class of peroxisome proliferator- activated receptor γ (PPARγ) agonists that exhibit antitumorigenic activity. In this study, the PPARγ-active compounds decreased HT-29, HCT-15, RKO, HCT116 and SW480 colon cancer cell survival and KU7 and 253JB-V33 bladder cancer cell survival. In HT- 29, HCT-15, SW480 and KU7 cells, the PPARγ agonists induced caveolin-1 expression and this induction was significantly downregulated after cotreatment with the PPARγ antagonist GW9662.
    [Show full text]
  • The Use of Immortalized Hepatocytes in Induction Studies
    THE USE OF IMMORTALIZED HEPATOCYTES IN INDUCTION STUDIES Kevin Lyon, Maciej Czerwinski, Martin Perry, Paul Toren and Andrew Parkinson Kevin Lyon, Maciej Czerwinski, Martin Perry, Paul Toren and Andrew Parkinson XENOTECH XenoTech LLC, 1682516825 West 116th Street, LeneLenexa, KSKS 6621966219 INTRODUCTION RESULTS Figure 3: CONCLUSIONS CYP1A2: Phenacetin CYP2B6: Bupropion Primary cultures of human hepatocytes are widely used to 1. Fa2N-4 cells metabolize CYP-specific substrates. In Fa2N-4 Figure 2: Time course of CYP3A4 induction in Fa2N-4 cells 5 1. The Fa2N-4 cells respond like primary evaluate the cytochrome P450 (CYP) enzyme-inducing cells, activity of phenacetin O-dealkylase (CYP1A2) increased 1000 CYP induction 10 cultures of human hepatocytes to a wide 4 potential and/or toxicity of drug candidates. However, the 11 fold in response to three days' treatment with 100 µM in Fa2N-4 cells 800 range of xenobiotics. The Fa2N-4 cells nduction 5 availability of human hepatocytes for this purpose is limited 600 3 140 omeprazole. In response to a three-day treatment with 20 µM respond to prototypical PXR and AhR 400 2 old I and erratic, and there are large inter-individual differences in rifampin, the rates of midazolam 1´-hydroxylation (CYP3A4), 120 F 0 1 2 3 4 5 6 (pmol/incubation) (pmol/incubation) agonists in a manner that closely Acetaminophen 200 1 xylation the magnitude of induction (due to differences in both Hydroxybupropion Exposure Period (days) bupropion hydroxylation (CYP2B6), and diclofenac 4´- o 100 resembles the magnitude of induction "control" and "induced" CYP activities). Immortalized 0 0 dr hydroxylation (CYP2C9) increased by 4.9, 2.2, and 4.0 fold, y DMSO Omeprazole DMSO Rifampin 80 observed in freshly plated hepatocytes human hepatocytes, Fa2N-4, developed by Multicell -h 0.1% DMSO respectively.
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Design, Synthesis, and Evaluation of Thiazolidinedione Derivatives Inhibiting Bcl-2/Bcl-Xl Or Ablating Androgen Receptor for the Treatment of Prostate Cancer
    DESIGN, SYNTHESIS, AND EVALUATION OF THIAZOLIDINEDIONE DERIVATIVES INHIBITING BCL-2/BCL-XL OR ABLATING ANDROGEN RECEPTOR FOR THE TREATMENT OF PROSTATE CANCER DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Jian Yang, M.S. * * * * * The Ohio State University 2009 Dissertation Committee: Approved by Professor Ching-Shih Chen, Advisor Professor Pui-Kai (Tom) Li Adviser Professor Werner Tjarks Pharmacy Gradate Program Professor Dale Hoyt COPYRIGHT BY JIAN YANG 2009 ABSTRACT As of 2008, prostate cancer remains the number one cause of estimated new cancer cases in American men. Although early prostate cancer responds to androgen ablation, most tumors eventually recur as hormone-refractory prostate cancer (HRPC). Recent advances have identified many abnormal signaling pathways that contribute to the development of HRPC, mainly including dysregulation of androgen receptor (AR) function and the over- expression of the anti-apoptotic proteins, Bcl-2/Bcl-xL. It was found that thiazolidinediones (TZD), which include the anti-diabetic agents troglitazone, rosiglitazone, pioglitazone and ciglitazone, possess anti-tumor activity. It has been revealed that the anti-tumor activity of the TZDs could be attributed to PPARγ- independent mechanisms including Bcl-2/Bcl-xL inhibition and AR transcriptional repression. The objective of this dissertation is to further modify the TZD structures to enhance anti-prostate cancer activity by targeting the dysregulated Bcl-2/Bcl-xL and AR signaling pathways. Directed by method of molecular modeling, over 50 troglitazone derivatives have been designed and synthesized in two stages, yielding the optimal compound HepCNCF3, which showed two orders of magnitude improvement in Bcl-xL/Bcl-2 inhibition ii compared to troglitazone.
    [Show full text]
  • Medical Treatments for Endometriosis-Associated Pelvic Pain
    Hindawi Publishing Corporation BioMed Research International Volume 2014, Article ID 191967, 12 pages http://dx.doi.org/10.1155/2014/191967 Review Article Medical Treatments for Endometriosis-Associated Pelvic Pain Gabriella Zito,1 Stefania Luppi,2 Elena Giolo,2 Monica Martinelli,2 Irene Venturin,1 Giovanni Di Lorenzo,1 and Giuseppe Ricci1,2 1 Department of Medical Sciences, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy 2 Institute for Maternal and Child Health, IRCCS “Burlo Garofolo”, Via dell’Istria 65/1, 34137 Trieste, Italy Correspondence should be addressed to Giuseppe Ricci; [email protected] Received 17 November 2013; Accepted 26 May 2014; Published 7 August 2014 Academic Editor: Mohamed Mabrouk Copyright © 2014 Gabriella Zito et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The main sequelae of endometriosis are represented by infertility and chronic pelvic pain. Chronic pelvic pain causes disability and distress with a very high economic impact. In the last decades, an impressive amount of pharmacological agents have been tested for the treatment of endometriosis-associated pelvic pain. However, only a few of these have been introduced into clinical practice. Following the results of the controlled studies available, to date, the first-line treatment for endometriosis associated pain is still represented by oral contraceptives used continuously. Progestins represent an acceptable alternative. In women with rectovaginal lesions or colorectal endometriosis, norethisterone acetate at low dosage should be preferred. GnRH analogues may be used as second-line treatment, but significant side effects should be taken into account.
    [Show full text]
  • Ciglitazone—A Human Pparγ Agonist—Disrupts Dorsoventral Patterning in Zebrafish
    Ciglitazone—a human PPARγ agonist— disrupts dorsoventral patterning in zebrafish Vanessa Cheng, Subham Dasgupta, Aalekhya Reddam and David C. Volz Department of Environmental Sciences, University of California, Riverside, CA, USA ABSTRACT Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription factor that regulates lipid/glucose homeostasis and adipocyte differentiation. While the role of PPARγ in adipogenesis and diabetes has been extensively studied, little is known about PPARγ function during early embryonic development. Within zebrafish, maternally-loaded pparγ transcripts are present within the first 6 h post-fertilization (hpf), and de novo transcription of zygotic pparγ commences at ~48 hpf. Since maternal pparγ transcripts are elevated during a critical window of cell fate specification, the objective of this study was to test the hypothesis that PPARγ regulates gastrulation and dorsoventral patterning during zebrafish embryogenesis. To accomplish this objective, we relied on (1) ciglitazone as a potent PPARγ agonist and (2) a splice-blocking, pparγ-specific morpholino to knockdown pparγ. We found that initiation of ciglitazone—a potent human PPARγ agonist—exposure by 4 hpf resulted in concentration-dependent effects on dorsoventral patterning in the absence of epiboly defects during gastrulation, leading to ventralized embryos by 24 hpf. Interestingly, ciglitazone-induced ventralization was reversed by co-exposure with dorsomorphin, a bone morphogenetic protein signaling inhibitor that induces strong dorsalization within zebrafish embryos. Moreover, mRNA-sequencing revealed that lipid- and cholesterol-related processes were affected by exposure to ciglitazone. However, pparγ knockdown did not block γ Submitted 16 August 2019 ciglitazone-induced ventralization, suggesting that PPAR is not required for Accepted 17 October 2019 dorsoventral patterning nor involved in ciglitazone-induced toxicity within Published 13 November 2019 zebrafish embryos.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,383,154 B2 Bar-Shalom Et Al
    USOO8383154B2 (12) United States Patent (10) Patent No.: US 8,383,154 B2 Bar-Shalom et al. (45) Date of Patent: Feb. 26, 2013 (54) SWELLABLE DOSAGE FORM COMPRISING W W 2.3. A. 3. 2. GELLAN GUMI WO WOO1,76610 10, 2001 WO WOO2,46571 A2 6, 2002 (75) Inventors: Daniel Bar-Shalom, Kokkedal (DK); WO WO O2/49571 A2 6, 2002 Lillian Slot, Virum (DK); Gina Fischer, WO WO 03/043638 A1 5, 2003 yerlosea (DK), Pernille Heyrup WO WO 2004/096906 A1 11, 2004 Hemmingsen, Bagsvaerd (DK) WO WO 2005/007074 1, 2005 WO WO 2005/007074 A 1, 2005 (73) Assignee: Egalet A/S, Vaerlose (DK) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 JECFA, “Gellangum”. FNP 52 Addendum 4 (1996).* U.S.C. 154(b) by 1259 days. JECFA, “Talc”, FNP 52 Addendum 1 (1992).* Alterna LLC, “ElixSure, Allergy Formula', description and label (21) Appl. No.: 111596,123 directions, online (Feb. 6, 2007). Hagerström, H., “Polymer gels as pharmaceutical dosage forms'. (22) PCT Filed: May 11, 2005 comprehensive Summaries of Uppsala dissertations from the faculty of pharmacy, vol. 293 Uppsala (2003). (86). PCT No.: PCT/DK2OOS/OOO317 Lin, “Gellan Gum', U.S. Food and Drug Administration, www. inchem.org, online (Jan. 17, 2005). S371 (c)(1), Miyazaki, S., et al., “In situ-gelling gellan formulations as vehicles (2), (4) Date: Aug. 14, 2007 for oral drug delivery”. J. Control Release, vol. 60, pp. 287-295 (1999). (87) PCT Pub. No.: WO2005/107713 Rowe, Raymond C.
    [Show full text]